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S184 Oral PresentationsChimerism studies were done using STR at 1, 3, 6, 9 and 12
months post transplant and 3 monthly thereafter. All but one child
engrafted but 4 children had early autologous reconstitution. At 1
year post SCT65%, 9%, 9%and 7%had complete donor chimerism
(CC), highMC (50-95%donor chimerism), lowMC (10-49% donor
chimerism) and very lowMC (\10% donor chimerism) respectively
and these were stable at last follow-up. All childrenwithCC and high
MC are cured of their disease. 26 children (17%) had low or very low
MC. The incidence of low and very lowMCwas significantly higher
with BM (24/109,22%) than with PBSC (2/41,5%).Children with
low and very low levelMChad a poorer prognosis: 5/26 needed a sec-
ond transplant, 3/26 died, 2 had DLI, 1 CD34 top-up, 1 has ongoing
poor immune reconstitution. In conclusion, use of PBSC leads to
good long term chimerism with acceptable GVHD and we advocate
that PBSC should be the stem cell source of choice in RIC SCT in
children.78
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Background: In hematopoietic stem cell transplantation (HSCT)
the occurrence of single nucleotide polymorphisms (SNPs)
within the NOD2/CARD15 gene are associated with higher
susceptibility for graft-versus-host disease (GvHD). Idiopathic
pulmonary syndrome (IPS) is a non-infectious early onset lung
disease (\100days) after HSCT and associated with high mortal-
ity rates. Exact pathogenesis is unknown, but IPS could be con-
sidered as an allo-reactive disease. We retrospectively studied the
clinical impact of NOD2-variants in pediatric HSCT patients
with IPS.
Methods: All patients transplanted between 2004 and 2006 in the
UMCUwere included. For all recipient-donor pairs, mutation anal-
ysis for SNPs 8, 12 and 13 of the NOD2-gene was performed. IPS
was defined as respiratory symptoms with infiltrative changes on
chest X-ray without a direct infectious cause identified (excluding
a respiratory virus). An uni- and multivariable risk factor analyses
was performed using logistic regression and Cox proportional
Hazards.
Results: 57 HSCT patients (29 malignant and 28 for non-malignant
indication) were transplanted with 33 matched and 24 mismatched
donors. Median follow up was 19 months (8-36). The actual proba-
bility of disease free survival was 71%. IPS occurred in 9 patients at
a median of 7 weeks post-HSCT (range 3-12) of whom 4 died. NOD
polymorphisms were found in 6 recipients, 5 donors and in 4 both
donor and recipient. In multivariate regression analysis presence of
a respiratory virus after transplant (p5 0.032, OR 14.41, range
1.27-164.12) and presence of a NOD2-variant (in donor and/or
recipient: p5 0.046, OR 9.15, range 1.04 -80.44) were independent
variables influencing the endpoint IPS.
Conclusion: NOD2 polymorphisms may impact the development
of IPS in addition to the presence of respiratory viral infections. Al-
though more research is warranted on this topic it suggests that
avoiding NOD2 polymorphisms in donors as well as reducing the
pulmonary epithelial damage by screening for viral infections and/
or preventing viral infections prior to SCTmay be important to pre-
vent IPS.79
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Treosulfan is a bi-functional alkylating agent which causes less
VOD than busulphan and does not require anticonvulsant pro-
phylaxis and drug monitoring. We report the use of treosulfan in
70 children undergoing HCT for PID at two supraregional
transplant centres in the UK. Children received 42 g/m2 or 36 g/m2
treosulfan in combination with either cyclophosphamide 200 mg/kg
(30) or fludarabine 150 mg/m2 (40). All received Campath 1 H
0.3 mg/kg to1.0 mg/kg total dose except those with matched sibling
donors (n5 8), haploidentical CD3/CD19 depleted grafts (n5 3),
CD34+ selected graft with OKT3 (1) and 4 cords (3 of whom had
ATG).
Diagnoses were as follows: severe combined immunodeficiency
(26), Omenn’s Syndrome (7), Wiskott Aldrich syndrome (7), HLH
(5), leukocyte adhesion deficiency (4), chronic granulomatous dis-
ease (3), severe immune dysregulation (3), other PID (15).
Age at transplant ranged from 5 weeks to 14 years 8 months
(median 9 months). 47 patients were 12 months or younger.
Donors were as follows: MSD (8 -1 cord); MFD (13); haploident-
ical (4); URD (45:HLA matched 7-10/10). 16 of 45 were cords (7-
10/10 HLA matched). Follow up is 2- 59 months (median 16
months).
Overall survival was 81%. 13 children died: 6/40 in the treo-
sulfan/fludarabine group and 7/30 in the treosulfan/cyclophos-
phamide group- HLH disease D-1, graft rejection and CMV,
infection (4), GVHD, GVHD+infection etc. Skin toxicity was
common. VOD occurred in 2 children in combination with
cyclophosphamide and both had enterovirus in the gut. 2 patients
rejected (MHC II deficiency successfully retransplanted, ALPS
patient died of CMV before retransplant). Of patients more
than 6 months post transplant 19/28 (68%) who had treosul-
fan/fludarabine and 14/22 (64%) treosulfan/cyclophosphamide
have 100% donor chimerism. The remainder have stable mixed
chimerism.
Outcome is good with low regimen related toxicity. Treosulfan
plus fludarabine was particularly well tolerated. Immune reconstitu-
tion and chimerism were equivalent to busulphan containing regi-
mens. Long-term follow up is required.80
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Despite major advances in the field of hematopoietic cell trans-
plant (HCT) in recent years, significant life-threatening complica-
tions still occur. Quantifying this risk for individual patients,
however, is challenging. The HCT-CI combines important comor-
bidities with varying effect on treatment related morbidity and
mortality and combines them into one score. It has been confirmed
as a useful tool in adults undergoing HCT, but has not yet been
validated in children. We conducted a retrospective cohort study
of 252 consecutive pediatric patients undergoing their first alloge-
neic HCT at 4 large centers between January 2008 and May 2009.
Pre-transplant comorbidities were scored prospectively for each
patient using the HCT-CI. The impact of the HCT-CI score on
non-relapse mortality (NRM) and overall survival (OS) was then
analyzed. Underlying diagnoses included leukemia (n5 110),
immune deficiency (n5 63), storage disorders (n5 24), aplastic ane-
mia (n5 22), Fanconi anemia (n5 18), benign hematologic abnor-
malities (n5 9) and other (n5 6). The median age at transplant
was 6 years (range 0.1-20). Donor sources included matched related
donor (n5 74), mismatched related donor (n5 21), HLA matched
unrelated donor (n5 75), mismatched unrelated donor (n5 34)
